What Is the Difference Between Retatrutide and Tesamorelin?
The two compounds are often paired in research protocols specifically because their mechanisms are complementary rather than overlapping — Retatrutide's incretin-receptor activity and Tesamorelin's GH-axis stimulation approach body composition from different biological angles. REVIVE LAB UAE's own stack documentation lists them as a common companion pairing for exactly this reason.
Structurally they are unrelated: Retatrutide (≈4731 Da, 39 amino acids) is a triple receptor agonist, while Tesamorelin (≈5135 Da, 44 amino acids) is a modified fragment of growth hormone-releasing hormone. Retatrutide has Phase 2 trial data showing ≈24% mean body-weight reduction at 48 weeks; Tesamorelin has completed Phase 3 trials specifically for visceral adipose tissue reduction, with a different, narrower clinical endpoint.
Both are sold by REVIVE LAB UAE as separate SKUs — HPLC-verified, with individual Certificates of Analysis — strictly for laboratory research use, not for human or veterinary administration.
| Retatrutide | Tesamorelin | |
|---|---|---|
| Molecular weight | ≈ 4731 Da | ≈ 5135 Da |
| Sequence length | 39 amino acids | 44 amino acids |
| Receptor target | GLP-1 / GIP / Glucagon (triple agonist) | Pituitary GHRH receptor |
| Primary research focus | Weight reduction, glycemic control, NAFLD | Visceral adipose tissue, GH/IGF-1 axis |
| Clinical trial stage | Phase 2 (NEJM 2023) | Phase 3 completed (Egrifta indication) |
| HPLC purity (REVIVE LAB UAE) | ≥ 99.0% | ≥ 98.5% |
Purity ≥ 98.5% (HPLC) · COD, card or Binance Pay (5% off) Order Tesamorelin UAE — Live Stock & Pricing